Relation of the use of lipid-lowering medications prior to percutaneous coronary intervention to the incidence of intraprocedural adverse angiographic events

• Published in: The American journal of cardiology 2005-04, Vol.95 (8), p.978-980
• Main Authors: FERGUSON, Michael A, ROMICK, Benjamin G, CARTER, Luther I, DE GEARE, Vincent S
• Format: Article
• Language: English
• Subjects: Aged; Angioplasty, Balloon, Coronary - adverse effects; Biological and medical sciences; Cardiology. Vascular system; Coronary Angiography; Drug therapy; Female; Heart; Humans; Hyperlipidemias - drug therapy; Hypolipidemic Agents - administration & dosage; Hypolipidemic Agents - therapeutic use; Intraoperative Period; Lipids; Male; Medical sciences; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies; Surgery; Treatment Outcome
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2004.12.040

The use of lipid-lowering medications at the time of percutaneouscoronary intervention (PCI) has been shown to have a favorable effect on rates of cardiac enzyme elevation and major adverse cardiac events (MACEs), but the effect of these medications on angiographically identifiable intraprocedural coronary events during PCI has not previously been investigated. A retrospective review of 81 patients was performed and demonstrated that the use of lipid-lowering medications at the time of PCI was associated with a reduced incidence of angiographically identifiable intraprocedural events (odds ratio 0.13, 95% confidence interval 0.04 to 0.40). A multivariate analysis revealed that lipid-lowering medications and hyperlipidemia did not predict MACEs independent of the occurrence of these angiographic events.